BioSight
Companies
Lantheus Holdings, Inc. logo

LNTH

NASDAQNORTH BILLERICA, MA
Lantheus Holdings, Inc.

Lantheus Holdings manufactures diagnostic imaging agents used in nuclear medicine, including established commercial products like PYLARIFY (a prostate cancer imaging agent), DEFINITY (a cardiac imaging agent), and Neuraceq (a brain imaging agent). The company is also developing new imaging agents such as a new formulation of an F-18 PSMA PET imaging agent and other candidates, currently working to obtain FDA approvals and establish manufacturing capability across its network. Lantheus operates in the diagnostic imaging space rather than therapeutics, focusing on helping physicians visualize diseases rather than treat them.

Price history not yet available for LNTH.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar